方盛制药：洛索洛芬钠凝胶贴膏获得药品注册证书

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its wholly-owned subsidiary, Jianmeng Pharmaceutical, received approval from the National Medical Products Administration for the production of Loxoprofen Sodium Gel Patch, which is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after injuries [1] Group 1: Product Approval - The Loxoprofen Sodium Gel Patch has been granted a drug registration certificate, allowing it to be produced [1] - The active ingredient, Loxoprofen Sodium, is classified as a non-steroidal anti-inflammatory drug (NSAID) and is known for its significant anti-inflammatory and analgesic effects, particularly its strong analgesic properties [1] Group 2: Indications and Benefits - The gel patch is specifically indicated for osteoarthritis, muscle pain, and post-injury swelling pain [1] - The product is expected to provide effective anti-inflammatory and pain relief benefits to patients [1]